Skip to contentM
Marimed Inc.
M
MRMDMarimed Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$38.74M$38.74Mderived−0.4% vs Q4 2023 Net Income-$8.51M-$8.51MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marimed Inc. · CIK 1522767 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$12,450,000−28.1% Operating Incomederived-$1,713,000N/M Operating Cash Flowderived-$413,000N/M Free Cash Flowderived-$1,471,000N/M Margins · derivedGross margin32.1%−12.4 pt vs Q4 2023
Operating margin-4.4%−10.6 pt vs Q4 2023
Net margin-22.0%+4.2 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 6, 2025 · 65 d after period end